PNC Financial Services Group Inc. Has $9.71 Million Stake in Solventum Corporation $SOLV

PNC Financial Services Group Inc. trimmed its stake in Solventum Corporation (NYSE:SOLV) by 5.8% in the first quarter, Holdings Channel.com reports. The firm owned 148,679 shares of the company’s stock after selling 9,169 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Solventum were worth $9,709,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in SOLV. Independent Franchise Partners LLP grew its position in Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. Norges Bank purchased a new stake in Solventum in the 4th quarter worth approximately $147,467,000. Diamond Hill Capital Management Inc. lifted its position in Solventum by 152.2% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after buying an additional 1,272,921 shares in the last quarter. Boston Partners boosted its stake in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Solventum by 20.0% during the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Thursday, May 14th. Wells Fargo & Company lowered their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. KeyCorp upped their target price on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus reduced their price target on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $81.91.

Solventum Trading Up 1.0%

Shares of NYSE:SOLV opened at $78.02 on Friday. The stock has a market capitalization of $13.51 billion, a PE ratio of 9.56, a P/E/G ratio of 1.20 and a beta of 0.66. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The firm has a fifty day moving average price of $77.47 and a 200 day moving average price of $74.22. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business’s revenue was down 3.0% compared to the same quarter last year. During the same period last year, the company earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.